What's breaking now, across thousands of outlets.
On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
The development assumes significance for India's $60-billion pharmaceutical industry amid concerns over the quality of drugs manufactured in the country.
NY gov. pointed to Kennedy's long-standing anti-vaccine work as spurring outbreaks.
NY gov. pointed to Kennedy's long-standing anti-vaccine work as spurring outbreaks.
Around 200,000 cases of skin cancer are diagnosed in France every year. Yet as more and more patients seek medical advice, getting an appointment with a dermatologist is becoming increasingly…
Bioengineered retracted 119 papers in October amid investigations into suspected paper mill activity and other integrity-related concerns at the Taylor & Francis journal.
